Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2.
Zhengxin CaiSongye LiWenjie ZhangRichard PracittoXiaoai WuEvan BaumSjoerd J FinnemaDaniel HoldenTakuya ToyonagaShu-Fei LinMarcel LindemannAnupama ShiraliDavid C LabareeJim RopchanNabeel NabulsiRichard E CarsonYiyun HuangPublished in: ACS chemical neuroscience (2020)
Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new 18F-labeled SV2A PET imaging probe, [18F]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.
Keyphrases
- pet imaging
- traumatic brain injury
- multiple sclerosis
- positron emission tomography
- endothelial cells
- white matter
- living cells
- autism spectrum disorder
- quantum dots
- high resolution
- bipolar disorder
- computed tomography
- depressive symptoms
- atrial fibrillation
- binding protein
- prefrontal cortex
- cerebral ischemia
- mass spectrometry
- stem cells
- sleep quality
- transcription factor
- bone marrow
- pluripotent stem cells